乳癌诊断市场－全球产业规模、份额、趋势、机会和预测，按类型、产品、应用、最终用途、地区和竞争格局划分，2020-2030年预测

2024年全球乳癌诊断市场规模为629.8亿美元，预计2030年将以11.21%的复合年增长率成长至1,191.4亿美元。全球乳癌诊断市场涵盖一系列用于检测、鑑别和监测乳癌的专业检测、影像检查和活检程序。市场成长的主要驱动因素包括全球乳癌发生率的不断上升、公众健康意识宣传活动的加强以及政府为推广早期检测和筛检计画而采取的倡议。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球乳癌诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型（影像学检查、活检、基因组检测、血液检测、其他）
  • 依产品类型（平台型产品、仪器型产品）
  • 按应用领域（筛检、诊断和预测、预后、研究、其他）
  • 按最终用途（医院和诊所、诊断中心和医学实验室、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美乳癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲乳癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区乳癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲乳癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲乳癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球乳癌诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Baxter Pharmaceuticals India Private Limited.
• Bristol-Myers Squibb India Private Limited.
• Cipla Ltd.
• Roche Products (India) Private Limited.
• Glenmark Pharmaceuticals Ltd.
• Lupin Ltd
• Abbott India Laboratories Limited
• BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED.
• Siemens Healthcare Private Limited.
• Thermo Fisher Scientific India Private Limited.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Breast Cancer Diagnostics Market, valued at USD 62.98 Billion in 2024, is projected to experience a CAGR of 11.21% to reach USD 119.14 Billion by 2030. The Global Breast Cancer Diagnostics Market encompasses an array of specialized tests, imaging modalities, and biopsy procedures engineered to detect, characterize, and monitor breast cancer. Market growth is primarily driven by the escalating global incidence of breast cancer, augmented public health awareness campaigns, and governmental initiatives promoting early detection and screening programs.

Key Market Drivers

The increasing global incidence of breast cancer serves as a fundamental driver for the breast cancer diagnostics market. A rising number of new cases necessitates expanded screening and diagnostic capabilities worldwide to facilitate early detection and improve patient outcomes. This persistent disease burden creates consistent demand for diverse diagnostic solutions, from initial screening to definitive diagnosis and staging. For example, according to the American Cancer Society's Breast Cancer Facts & Figures 2024, an estimated 310,720 new cases of invasive breast cancer were expected to be diagnosed in the United States in 2024, underpinning the critical need for effective diagnostic tools. This widespread health challenge reinforces the market's expansion, with breast cancer being the most common cancer in women in 157 countries out of 185 in 2022, as reported by the World Health Organization in February 2024.

Key Market Challenges

The substantial cost associated with advanced diagnostic technologies represents a significant challenging factor impeding the growth of the Global Breast Cancer Diagnostics Market. These high expenses restrict accessibility to crucial screening and diagnostic procedures, particularly within developing economies where healthcare budgets are often constrained. This financial barrier limits the widespread adoption of comprehensive diagnostic screening protocols across various regions.

Key Market Trends

The growing adoption of liquid biopsy for early detection and monitoring represents a pivotal shift in breast cancer diagnostics. This non-invasive technique, which analyzes circulating tumor DNA or cells from a blood sample, offers a less burdensome alternative to traditional tissue biopsies, facilitating earlier detection and ongoing disease surveillance. Its utility is becoming increasingly recognized as research progresses, with clinical applications expanding beyond advanced disease. According to the American Society of Clinical Oncology, in January 2024, five liquid biopsy companion diagnostic assays were approved by the U. S. Food and Drug Administration for their clinical application in the diagnosis of cancer.

Key Market Players

• Baxter Pharmaceuticals India Private Limited.
• Bristol-Myers Squibb India Private Limited.
• Cipla Ltd.
• Roche Products (India) Private Limited.
• Glenmark Pharmaceuticals Ltd.
• Lupin Ltd
• Abbott India Laboratories Limited
• BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED.
• Siemens Healthcare Private Limited.
• Thermo Fisher Scientific India Private Limited.

Report Scope:

In this report, the Global Breast Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Diagnostics Market, By Type:

• Imaging
• Biopsy
• Genomic Tests
• Blood Tests
• Others

Breast Cancer Diagnostics Market, By Product:

• Platform-based Products
• Instrument-based Products

Breast Cancer Diagnostics Market, By Application:

• Screening
• Diagnostic and Predictive
• Prognostic
• Research
• Others

Breast Cancer Diagnostics Market, By End-use:

• Hospitals & Clinics
• Diagnostic Centers and Medical Laboratories
• Others

Breast Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Breast Cancer Diagnostics Market.

Available Customizations:

Global Breast Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Breast Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Imaging, Biopsy, Genomic Tests, Blood Tests, Others)
  • 5.2.2. By Product (Platform-based Products, Instrument-based Products)
  • 5.2.3. By Application (Screening, Diagnostic and Predictive, Prognostic, Research, Others)
  • 5.2.4. By End-use (Hospitals & Clinics, Diagnostic Centers and Medical Laboratories, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Breast Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Application
  • 6.2.4. By End-use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Breast Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End-use
  • 6.3.2. Canada Breast Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End-use
  • 6.3.3. Mexico Breast Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End-use

7. Europe Breast Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Application
  • 7.2.4. By End-use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Breast Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End-use
  • 7.3.2. France Breast Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End-use
  • 7.3.3. United Kingdom Breast Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End-use
  • 7.3.4. Italy Breast Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End-use
  • 7.3.5. Spain Breast Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End-use

8. Asia Pacific Breast Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Application
  • 8.2.4. By End-use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Breast Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End-use
  • 8.3.2. India Breast Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End-use
  • 8.3.3. Japan Breast Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End-use
  • 8.3.4. South Korea Breast Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End-use
  • 8.3.5. Australia Breast Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End-use

9. Middle East & Africa Breast Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Application
  • 9.2.4. By End-use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Breast Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End-use
  • 9.3.2. UAE Breast Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End-use
  • 9.3.3. South Africa Breast Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End-use

10. South America Breast Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Application
  • 10.2.4. By End-use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Breast Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End-use
  • 10.3.2. Colombia Breast Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End-use
  • 10.3.3. Argentina Breast Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End-use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Breast Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Baxter Pharmaceuticals India Private Limited.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bristol-Myers Squibb India Private Limited.
• 15.3. Cipla Ltd.
• 15.4. Roche Products (India) Private Limited.
• 15.5. Glenmark Pharmaceuticals Ltd.
• 15.6. Lupin Ltd
• 15.7. Abbott India Laboratories Limited
• 15.8. BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED.
• 15.9. Siemens Healthcare Private Limited.
• 15.10. Thermo Fisher Scientific India Private Limited.

16. Strategic Recommendations

17. About Us & Disclaimer